PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278802ArticlesСтатьиCLINICAL ASPECTS FOR USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN COMBINATION WITH METFORMIN: BENEFITS FOR DIFFERENT GROUPS OF PATIENTSКЛИНИЧЕСКИЕ АСПЕКТЫ ПРИМЕНЕНИЯ ИНГИБИТОРОВ ДИПЕПТИДИЛПЕПТАЗЫ-4 В КОМБИНАЦИИ С МЕТФОРМИНОМ: ПРЕИМУЩЕСТВА ДЛЯ РАЗНЫХ ГРУПП ПАЦИЕНТОВAntsiferovMikhail BorisovichАнциферовМихаил Борисович

Эндокринологический диспансер Департамента здравоохранения города Москвы

AntsiferovM BЭндокринологический диспансер Департамента здравоохранения города Москвы15022011183NO3 (2011)№3 (2011)505523022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278802

Mechanisms of action and potentials for use of dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin (Galvus) and its combined form with metformin (Galvus Met) in type 2 diabetes mellitus (DM2) are discussed. The article presents the results of numerous clinical trials that have proved efficacy of DPP-4 inhibitors, primarily Galvus and Galvus Met, in improvement of glycemic control without increasing body weight and frequency of hypoglycaemia. They can be used in combination with all oral hypoglycemic agents and insulin (vildagliptin) that expands the range of use due to different groups of patients with DM2.

Рассматриваются механизмы действия и возможности применения при сахарном диабете 2 типа (СД2) ингибитора дипептидилпептазы-4 (ДПП-4) вилдаглиптина (Галвус) и его комбинированной формы с метформином (Галвус Мет). Рассматриваются результаты многочисленных клинических испытаний, в которых показано, что препараты группы ингибиторов ДПП-4, в первую очередь Галвус и Галвус Мет, эффективно улучшают гликемический контроль, не повышая массу тела и частоту гипогликемий. Их можно использовать в комбинации со всеми пероральными сахароснижающими препаратами и инсулином (вилдаглиптин), что расширяет диапазон применения за счет различных групп пациентов с СД2.

type 2 diabetes mellitusincretinesdipeptidyl peptidase-4 inhibitorsvildagliptinmetforminGalvus Metсахарный диабет 2 типаинкретиныингибиторы дипептидилпептазы-4вилдаглиптинметформинГалвус МетUK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur Heart J 2008;29:969-83.DCCT/EDIC Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N Engl J Med 2003;348:2294-303.Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.AACE/ACE Consensus Statement Glycemic Control Algorithm, Endocr Pract. 2009;15(No. 6) 540-59.Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206.Fonseca V, at al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148-55.Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. М., 2010.Ahren B, Gomis R, Standl E, et al. Twelve- and 52-weeks efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80.Bosi E, Camisaca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-95.Croxtall JD, Keam SJ. Vildagliptin: a review of use in the management of type 2 diabetes mellitus. Drugs 2008;68(16):2387-409.Halimi S, Schweizer A, Minic B, et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vascular Health and Risk Management 2008;4(3):481-92.Matikainen N, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57.Boschmann M, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009;94:846-52.Schweizer A, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-61.Balas B, et al. The Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes. J Clin Endocrinol Metab 2007;92:1249-55.Ferrannini E, et al. 52-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157.Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diab Obes Metab 2010;12:780-89.Brooks J, et al. EASD 2009;Poster 750.Marfella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations J Diabetes Complications 2010; 24:79-83.